28 citations · 29 across the 5 of their papers we have counts for
5 papers
A mixture distribution approach for assessing genetic impact from twin study
Zonghui Hu, Pengfei Li, Dean Follmann +1
This work was motivated by a twin study with the goal of assessing the genetic control of immune traits. We propose a mixture bivariate distribution to model twin data where the un…
Mediation Analyses for the Effect of Antibodies in Vaccination
Michael P. Fay, Dean A. Follmann
We review standard mediation assumptions as they apply to identifying antibody effects in a randomized vaccine trial and propose new study designs to allow identification of an est…
Assessing Vaccine Durability in Randomized Trials Following Placebo Crossover
Jonathan Fintzi, Dean Follmann
Randomized vaccine trials are used to assess vaccine efficacy and to characterize the durability of vaccine induced protection. If efficacy is demonstrated, the treatment of placeb…
Endpoints for randomized controlled clinical trials for COVID-19 treatments
Lori E Dodd, Dean Follmann, Jing Wang +12
Introduction: Endpoint choice for randomized controlled trials of treatments for COVID-19 is complex. A new disease brings many uncertainties, but trials must start rapidly. COVID-…
Assessing surrogate endpoints in vaccine trials with case-cohort sampling and the Cox model
Li Qin, Peter B. Gilbert, Dean Follmann +1
Assessing immune responses to study vaccines as surrogates of protection plays a central role in vaccine clinical trials. Motivated by three ongoing or pending HIV vaccine efficacy…